In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo

Joseph H Friedman

doi:10.7326/ANNALS-24-01662-JC

In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo

Ann Intern Med. 2024 Sep;177(9):JC100. doi: 10.7326/ANNALS-24-01662-JC. Epub 2024 Sep 3.

Author

Joseph H Friedman¹

Affiliation

¹ Butler Hospital/Alpert Medical School of Brown University, Providence, Rhode Island, USA (J.H.F.).

PMID: 39222514
DOI: 10.7326/ANNALS-24-01662-JC

Abstract

Meissner WG, Remy P, Giordana C, et al; LIXIPARK Study Group. Trial of lixisenatide in early Parkinson's disease. N Engl J Med. 2024;390:1176-1185. 38598572.

Publication types

Comment